Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Leila Godfrey

PhD


Postdoctoral Immunologist

  • Post-doctoral scientist working on The Oxford Vaccine Centre’s COVID-19 vaccine trial, at The Jenner Institute

The Lambe Group

Working in the ChAdOx1 nCoV-19 trial team, I contribute to measuring the magnitude, longevity and phenotype of the T cell response to the SARS-CoV-2 vaccine. Lead for the variants trial, I am also collaborating with the Dong Group to explore in depth the vaccine response to challenge by emerging variants of concern.

Before The Jenner Institute, I worked with Professor John Todd at the Diabetes and Inflammation Laboratory (DIL) in the Wellcome Centre for Human Genetics. Here, I helped to develop a novel single cell sequencing technology which combines mRNA and protein quantitation. This new assay has now been used to explore regulatory T cell populations in autoimmune disease. I also performed flow cytometric phenotyping analyses for biomarker identification in clinical trial samples from patients with type 1 diabetes, with specialist training in the purification of specific lymphoid populations by flow cytometric sorting (BD FACSAria Fusion).

Prior to DIL, I worked for 2 years in Analytical Development at Immunocore, a Biotech with clinical stage T cell receptor therapies. My Doctoral training under Professor Margaret Callan at Imperial College London, studied the role of Natural Killer Cells in dysfunctional inflammation.